Which has stronger earnings & valuation, SHC or AZTA?

Sotera Health has higher revenue and earnings than Azenta. Azenta is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sotera Health $1.16B 4.51 $77.94M $0.57 32.23 Azenta $593.82M 2.28 -$55.76M -$2.76 N/A

Is SHC or AZTA more profitable?

Sotera Health has a net margin of 13.44% compared to Azenta's net margin of -20.63%. Sotera Health's return on equity of 40.12% beat Azenta's return on equity. Company Net Margins Return on Equity Return on Assets Sotera Health 13.44% 40.12% 7.55% Azenta -20.63% 1.18% 0.97%

Does the media favor SHC or AZTA?

In the previous week, Sotera Health had 3 more articles in the media than Azenta. MarketBeat recorded 8 mentions for Sotera Health and 5 mentions for Azenta. Sotera Health's average media sentiment score of 1.36 beat Azenta's score of 0.66 indicating that Sotera Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sotera Health 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Azenta 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AZTA or ADPT?

In the previous week, Azenta had 2 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 5 mentions for Azenta and 3 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.71 beat Azenta's score of 0.66 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Azenta 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor AZTA or ALMR?

In the previous week, Azenta had 3 more articles in the media than Alamar Biosciences. MarketBeat recorded 5 mentions for Azenta and 2 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 1.81 beat Azenta's score of 0.66 indicating that Alamar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Azenta 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer MRVI or AZTA?

In the previous week, Azenta had 3 more articles in the media than Maravai LifeSciences. MarketBeat recorded 5 mentions for Azenta and 2 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 1.79 beat Azenta's score of 0.66 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Azenta 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, FTRE or AZTA?

Azenta has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fortrea $2.68B 0.61 -$986.20M -$0.91 N/A Azenta $593.82M 2.28 -$55.76M -$2.76 N/A

Is FTRE or AZTA more profitable?

Fortrea has a net margin of -3.18% compared to Azenta's net margin of -20.63%. Fortrea's return on equity of 10.72% beat Azenta's return on equity. Company Net Margins Return on Equity Return on Assets Fortrea -3.18% 10.72% 2.17% Azenta -20.63% 1.18% 0.97%

Does the media favor FTRE or AZTA?

In the previous week, Fortrea had 5 more articles in the media than Azenta. MarketBeat recorded 10 mentions for Fortrea and 5 mentions for Azenta. Azenta's average media sentiment score of 0.66 beat Fortrea's score of 0.60 indicating that Azenta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortrea 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Azenta 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Azenta (AZTA) Competitors

$30.86 +0.68 (+2.25%)

Closing price 04:00 PM Eastern

Extended Trading

$30.85 -0.01 (-0.04%)

As of 05:01 PM Eastern

Compare

AZTA vs. SHC, ADPT, ALMR, MRVI, and FTRE

Should you buy Azenta stock or one of its competitors? Azenta's main competitors and comparable companies include Sotera Health (SHC), Adaptive Biotechnologies (ADPT), Alamar Biosciences (ALMR), Maravai LifeSciences (MRVI), and Fortrea (FTRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Azenta compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and Azenta (NASDAQ:AZTA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Sotera Health presently has a consensus target price of $21.50, suggesting a potential upside of 17.04%. Azenta has a consensus target price of $41.20, suggesting a potential upside of 33.51%. Given Azenta's higher possible upside, analysts clearly believe Azenta is more favorable than Sotera Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Sotera Health has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Azenta has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market.

Sotera Health has a net margin of 13.44% compared to Azenta's net margin of -20.63%. Sotera Health's return on equity of 40.12% beat Azenta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	13.44%	40.12%	7.55%
Azenta	-20.63%	1.18%	0.97%

91.0% of Sotera Health shares are held by institutional investors. Comparatively, 99.1% of Azenta shares are held by institutional investors. 15.4% of Sotera Health shares are held by company insiders. Comparatively, 10.9% of Azenta shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Sotera Health had 3 more articles in the media than Azenta. MarketBeat recorded 8 mentions for Sotera Health and 5 mentions for Azenta. Sotera Health's average media sentiment score of 1.36 beat Azenta's score of 0.66 indicating that Sotera Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sotera Health	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Azenta	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sotera Health has higher revenue and earnings than Azenta. Azenta is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.16B	4.51	$77.94M	$0.57	32.23
Azenta	$593.82M	2.28	-$55.76M	-$2.76	N/A

Summary

Sotera Health beats Azenta on 14 of the 16 factors compared between the two stocks.

How does Azenta compare to Adaptive Biotechnologies?

Azenta (NASDAQ:AZTA) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

99.1% of Azenta shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 10.9% of Azenta shares are owned by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Azenta has a net margin of -20.63% compared to Adaptive Biotechnologies' net margin of -20.73%. Azenta's return on equity of 1.18% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Azenta	-20.63%	1.18%	0.97%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

Azenta has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Azenta	$593.82M	2.28	-$55.76M	-$2.76	N/A
Adaptive Biotechnologies	$308.08M	12.53	-$59.50M	-$0.41	N/A

Azenta has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market.

In the previous week, Azenta had 2 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 5 mentions for Azenta and 3 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.71 beat Azenta's score of 0.66 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Azenta	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Azenta presently has a consensus price target of $41.20, suggesting a potential upside of 33.51%. Adaptive Biotechnologies has a consensus price target of $24.42, suggesting a potential upside of 0.98%. Given Azenta's higher possible upside, analysts plainly believe Azenta is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Azenta beats Adaptive Biotechnologies on 9 of the 16 factors compared between the two stocks.

How does Azenta compare to Alamar Biosciences?

Azenta (NASDAQ:AZTA) and Alamar Biosciences (NASDAQ:ALMR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, Azenta had 3 more articles in the media than Alamar Biosciences. MarketBeat recorded 5 mentions for Azenta and 2 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 1.81 beat Azenta's score of 0.66 indicating that Alamar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Azenta	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Alamar Biosciences has a net margin of 0.00% compared to Azenta's net margin of -20.63%. Azenta's return on equity of 1.18% beat Alamar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Azenta	-20.63%	1.18%	0.97%
Alamar Biosciences	N/A	N/A	N/A

Alamar Biosciences has lower revenue, but higher earnings than Azenta. Alamar Biosciences is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Azenta	$593.82M	2.28	-$55.76M	-$2.76	N/A
Alamar Biosciences	$74.21M	26.11	-$29.82M	-$1.96	N/A

99.1% of Azenta shares are owned by institutional investors. 10.9% of Azenta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Azenta currently has a consensus target price of $41.20, indicating a potential upside of 33.51%. Alamar Biosciences has a consensus target price of $31.80, indicating a potential upside of 13.90%. Given Azenta's higher possible upside, equities research analysts clearly believe Azenta is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Azenta beats Alamar Biosciences on 8 of the 13 factors compared between the two stocks.

How does Azenta compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Azenta (NASDAQ:AZTA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 99.1% of Azenta shares are held by institutional investors. 2.5% of Maravai LifeSciences shares are held by company insiders. Comparatively, 10.9% of Azenta shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Azenta had 3 more articles in the media than Maravai LifeSciences. MarketBeat recorded 5 mentions for Azenta and 2 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 1.79 beat Azenta's score of 0.66 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Azenta	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Azenta has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	9.13	-$130.77M	-$0.52	N/A
Azenta	$593.82M	2.28	-$55.76M	-$2.76	N/A

Maravai LifeSciences currently has a consensus target price of $6.83, suggesting a potential upside of 4.65%. Azenta has a consensus target price of $41.20, suggesting a potential upside of 33.51%. Given Azenta's stronger consensus rating and higher probable upside, analysts plainly believe Azenta is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Maravai LifeSciences has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Azenta has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

Azenta has a net margin of -20.63% compared to Maravai LifeSciences' net margin of -37.07%. Azenta's return on equity of 1.18% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
Azenta	-20.63%	1.18%	0.97%

Summary

Azenta beats Maravai LifeSciences on 13 of the 16 factors compared between the two stocks.

How does Azenta compare to Fortrea?

Fortrea (NASDAQ:FTRE) and Azenta (NASDAQ:AZTA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

In the previous week, Fortrea had 5 more articles in the media than Azenta. MarketBeat recorded 10 mentions for Fortrea and 5 mentions for Azenta. Azenta's average media sentiment score of 0.66 beat Fortrea's score of 0.60 indicating that Azenta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortrea	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Azenta	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortrea has a beta of 1.97, suggesting that its stock price is 97% more volatile than the broader market. Comparatively, Azenta has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

Azenta has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.68B	0.61	-$986.20M	-$0.91	N/A
Azenta	$593.82M	2.28	-$55.76M	-$2.76	N/A

Fortrea presently has a consensus price target of $22.00, suggesting a potential upside of 27.91%. Azenta has a consensus price target of $41.20, suggesting a potential upside of 33.51%. Given Azenta's stronger consensus rating and higher possible upside, analysts clearly believe Azenta is more favorable than Fortrea.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Fortrea has a net margin of -3.18% compared to Azenta's net margin of -20.63%. Fortrea's return on equity of 10.72% beat Azenta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
Azenta	-20.63%	1.18%	0.97%

99.1% of Azenta shares are held by institutional investors. 0.7% of Fortrea shares are held by insiders. Comparatively, 10.9% of Azenta shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Fortrea and Azenta tied by winning 8 of the 16 factors compared between the two stocks.

Get Azenta News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AZTA vs. The Competition

Export

Metric	Azenta	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.35B	$9.75B	$7.12B	$12.83B
Dividend Yield	N/A	1.47%	2.56%	10.57%
P/E Ratio	-11.18	66.42	272.98	25.18
Price / Sales	2.28	108.15	620.42	83.61
Price / Cash	16.64	26.20	77.33	51.83
Price / Book	0.82	5.28	10.33	6.20
Net Income	-$55.76M	$56.67B	$3.49B	$358.38M
7 Day Performance	-1.50%	-2.08%	-3.25%	-2.35%
1 Month Performance	-7.58%	-2.14%	-0.23%	-2.60%
1 Year Performance	-1.12%	22.54%	17.33%	8.08%

Azenta Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AZTA Azenta	2.4879 of 5 stars	$30.86 +2.3%	$41.20 +33.5%	+3.1%	$1.35B	$593.82M	N/A	3,000
SHC Sotera Health	4.3165 of 5 stars	$18.90 -1.9%	$21.50 +13.8%	+16.0%	$5.50B	$1.16B	33.16	3,000	Positive News Analyst Forecast
ADPT Adaptive Biotechnologies	2.0871 of 5 stars	$24.92 -1.1%	$24.42 -2.0%	+95.1%	$4.02B	$276.98M	N/A	790	Positive News
ALMR Alamar Biosciences	2.5167 of 5 stars	$30.54 -0.6%	$31.80 +4.1%	N/A	$2.13B	$74.21M	N/A	222	Positive News
MRVI Maravai LifeSciences	1.8097 of 5 stars	$7.64 -0.5%	$6.25 -18.2%	+158.8%	$1.99B	$185.74M	N/A	610	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AZTA) was last updated on 9/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Azenta (AZTA) Competitors

AZTA vs. SHC, ADPT, ALMR, MRVI, and FTRE

How does Azenta compare to Sotera Health?

Summary

How does Azenta compare to Adaptive Biotechnologies?

Summary

How does Azenta compare to Alamar Biosciences?

Summary

How does Azenta compare to Maravai LifeSciences?

Summary

How does Azenta compare to Fortrea?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZTA vs. The Competition

Azenta Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Azenta (AZTA) Competitors

AZTA vs. SHC, ADPT, ALMR, MRVI, and FTRE

How does Azenta compare to Sotera Health?

Do analysts rate SHC or AZTA?

Which has more risk and volatility, SHC or AZTA?

Is SHC or AZTA more profitable?

Do insiders & institutionals hold more shares of SHC or AZTA?

Does the media favor SHC or AZTA?

Which has stronger earnings & valuation, SHC or AZTA?

Summary

How does Azenta compare to Adaptive Biotechnologies?

Do insiders & institutionals hold more shares of AZTA or ADPT?

Is AZTA or ADPT more profitable?

Which has better valuation & earnings, AZTA or ADPT?

Which has more risk & volatility, AZTA or ADPT?

Does the media refer more to AZTA or ADPT?

Do analysts prefer AZTA or ADPT?

Summary

How does Azenta compare to Alamar Biosciences?

Does the media favor AZTA or ALMR?

Is AZTA or ALMR more profitable?

Which has preferable earnings & valuation, AZTA or ALMR?

Do institutionals & insiders have more ownership in AZTA or ALMR?

Do analysts recommend AZTA or ALMR?

Summary

How does Azenta compare to Maravai LifeSciences?

Do insiders & institutionals believe in MRVI or AZTA?

Does the media prefer MRVI or AZTA?

Which has higher valuation and earnings, MRVI or AZTA?

Do analysts rate MRVI or AZTA?

Which has more volatility and risk, MRVI or AZTA?

Is MRVI or AZTA more profitable?

Summary

How does Azenta compare to Fortrea?

Does the media favor FTRE or AZTA?

Which has more volatility & risk, FTRE or AZTA?

Which has preferable earnings & valuation, FTRE or AZTA?

Do analysts rate FTRE or AZTA?

Is FTRE or AZTA more profitable?

Do insiders and institutionals believe in FTRE or AZTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZTA vs. The Competition

Azenta Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools